CureVac Fails in Pivotal COVID-19 Vaccine Trial With 47 Percent Efficacy

Ludwig Burger wrote the following article in Reuters:German biotech CureVac NV (5CV.DE) said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study’s main go ...

17 Jun, 17:28